Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Praxis Precision Medicines, Inc.

< Previous 1 2 Next >
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Participate in Upcoming Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Participate in Upcoming April Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Present at Two February Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.